Local control, safety, and survival following image-guided percutaneous microwave thermal ablation in primary lung malignancy.


Journal

Clinical radiology
ISSN: 1365-229X
Titre abrégé: Clin Radiol
Pays: England
ID NLM: 1306016

Informations de publication

Date de publication:
01 2019
Historique:
received: 08 02 2018
accepted: 14 09 2018
pubmed: 19 11 2018
medline: 28 10 2019
entrez: 19 11 2018
Statut: ppublish

Résumé

To determine local control, safety, and survival following percutaneous computed tomography (CT)-guided high-power microwave ablation (MWA) in the treatment of primary lung malignancy at a single institution. From July 2010 to June 2016, 52 patients (mean age 76.3 years, range 55-91 years) with 61 unresectable primary lung cancers of mean diameter 23.8 mm (range 26-55 mm) underwent MWA in 55 ablation sessions. Tumours were diagnosed at biopsy, or positron-emission tomography (PET) avidity (mean SUV max = 10.51) and interval growth. Statistical analysis was performed by Kaplan-Meier modelling and Cox and logistic regression. Local tumour progression (LTP) was diagnosed in six lesions (10%). Median time to local recurrence was 3 months (range 2-14 months). There was a near 12-fold increased odds of local recurrence if the lesion size was >3 cm (95% confidence interval [CI]: 1.84-75.14; p=0.009). The median inpatient stay was 1 day, with no intra-procedural deaths and a 0% 30-day post-ablation mortality rate. Pneumothorax requiring drain was the most serious complication, occurring in 22% (n=12) of patients. Presence of severe emphysema and predicted forced expiratory volume in 1 second (FEV1) of <50% were found to predict future requirement of a drain (odds ratio [OR] 8.17, 95% CI: 1.62-41.37, p=0.01 and OR: 5.14, 95% CI: 1.28-20.68, p=0.02 respectively), when adjusted for age and gender. Tumour size >3 cm had a hazard ratio of 4.37 compared with tumour size ≤3 cm (95% CI: 1.45-13.17, p=0.009) of risk of cancer death at any time, by Cox regression. MWA for primary lung malignancy is a safe and effective treatment for primary lung tumours with outcomes that may be comparable to stereotactic body radiation therapy.

Identifiants

pubmed: 30447997
pii: S0009-9260(18)30551-8
doi: 10.1016/j.crad.2018.09.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

80.e19-80.e26

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

M T Tsakok (MT)

Department of Radiology, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK.

M W Little (MW)

Department of Radiology, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK.

G Hynes (G)

Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

R S Millington (RS)

Department of Radiology, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK.

P Boardman (P)

Department of Radiology, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK.

F V Gleeson (FV)

Department of Radiology, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK.

E M Anderson (EM)

Department of Radiology, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK. Electronic address: ewan.anderson@ouh.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH